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We report the synthesis of Fe3O4@mSiO2 nanostructures of different meso-silica (mSiO2) shell thickness, their
biocompatibility and behaviors for loading and release of a model drug ibuprofen. The composite nanostructures
have superparamagnetic magnetite cores of 208 nm average size and meso-silica shells of 15 to 40 nm thickness.
A modified Stöber method was used to grow the meso-silica shells over the hydrothermally grown monodispersed
magnetite particles. The composite nanoparticles show very promising drug holding and releasing behaviors,
which depend on the thickness of meso-silica shell. The biocompatibility of the meso-silica-coated and uncoated
magnetite nanoparticles was tested through cytotoxicity assay on breast cancer (MCF-7), ovarian cancer (SKOV3),
normal human lung fibroblasts MRC-5, and IMR-90 cells. The high drug holding capacity and reasonable biocompatibility
of the nanostructures make them ideal agents for targeted drug delivery applications in human body.
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In recent decades, nanotechnology has made great strides
in the design of new materials, with distinct characteristics
and functionalities suitable for applications in specific
areas such as in biomedicine [1], targeted drug delivery
[2–4], and photodegradation of environmental pollutants
[5–7]. For targeted drug delivery applications, one of the
main challenges is to develop nanostructures that can be
loaded with special drug and can be transported to certain
specific location of the body in a simple manner [8]. In
this regard, magnetite has been the most studied material,
especially as T2 contrast agent in MRI [9] due to its
biocompatibility and adequate magnetic properties. When
the magnetite is synthesized at nanoscale, its magnetic
properties change from ferromagnetic to superparamag-
netic, extending its application to biomedicine [10–12].
However, when magnetite nanoparticles are naked, they
get agglomerated due to high magnetic interaction and
high surface area. Moreover, in biological media, they
can be easily oxidized to form other phases. On the
other hand, reticuloendothelial system (RES) of human
body takes up bigger (>300 nm) magnetite nanoparticles* Correspondence: upal@ifuap.buap.mx
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reproduction in any medium, provided the origfrom circulatory blood more quickly than smaller sizes
[13, 14]. Therefore, it is necessary to functionalize magnet-
ite nanoparticles modifying their surface characteristics or
cover them properly by another biocompatible material to
avoid these disadvantages [15–18]. Frequently, mesopo-
rous silica (meso-silica) has been utilized as vehicle for the
delivery of special drugs [19–21] due its good biocompati-
bility in human body and high specific surface area (high
drug loading capacity). However, the problem arises when
we need to bring the drug to a specific site using meso-
silica as vehicle. Therefore, it is necessary to functiona-
lize such mesostructures in a special way to achieve the
objectives [22].
Magnetite nanoparticles covered with meso-silica shells
(Fe3O4@mSiO2) have been seen to be the most promising
material, fulfilling most of the abovementioned criteria for
applying them as vehicles for delivering special drugs
at specific sites of human body. While Xu et al. [23] have
developed Fe3O4@nSiO2@mSiO2 composite nanoparticles
with average size of about 400 nm, with good (about 95 %
in 85 hours) drug (ibuprofen)-releasing properties, Xu and
collaborators [24] fabricated hollow Fe3O4@SiO2 spheres
of about 900 nm average size with high drug (aspirin)
loading and sustained drug-releasing capacity. However,
the sizes of their nanoparticles are not perfectly suitable
for targeted drug delivery, as nanoparticles below 300 nmhis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
200 nm200 nm















Fig. 1 Typical SEM images of Fe3O4 nanoclusters (M-1) in two
magnifications. Their size distribution histogram is presented as inset
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report the synthesis of magnetite core meso-silica shell
composite nanoparticles of different shell thicknesses
using hydrothermal and sol–gel techniques. The struc-
ture, morphology, and texture characteristics of the
nanostructures have been studied using SEM, TEM, and
nitrogen adsorption–desorption techniques. The drug-
holding and -releasing capacity of the nanostructures
have been studied using ibuprofen as a model drug. Fi-
nally, we tested the cytotoxicity of nanostructures to
check their biocompatibility with the human body.
Methods
Chemicals and Solvents
Ferric chloride hexahydrate (FeCl3·6H2O, 97 %), anhydrous
sodium acetate (NaAc) (CH3COONa, 99.9 %), tetraethy-
lorthosilicate (TEOS), cetyltrimethylammonium bromide
(CTAB), glacial acetic acid, and ibuprofen were obtained
from Sigma-Aldrich, St. Louis, MO, USA. Ethylene glycol
(EG, C2H6O2, 99.7 %) was purchased from J. T. Baker,
Naucalpan, Edo. de México, Mexico. E-pure deionized
(DI) water (ρ > 18.2 Ω·cm) was used as solvent for wash-
ing. All the chemicals were of analytical grade and used
without further purification.
Synthesis of Magnetite (Fe3O4) Nanoparticles
Magnetite nanoparticles were synthesized through EG
mediated solvothermal process following the procedure
we reported earlier [26]. In a typical synthesis process,
first a 0.6-M solution of FeCl3 in EG was prepared by
dissolving 1.6211 g of FeCl3·6H2O in 10 mL of EG. The
solution was added to 40 mL of EG in a three-necked
round bottom flask under Ar atmosphere under mag-
netic agitation. After 30 min of stirring, 10 mL of 1.2 M
sodium acetate solution in EG was added to the previous
mixture under vigorous stirring. The stirring process
was continued for another 3 hours, and then the mixture
was transferred to a Teflon-lined stainless steel autoclave
and heated at 190 °C for 24 hours. Finally, the autoclave
was cooled down to room temperature, and the product
was magnetically separated, washed with water and etha-
nol several times, and dried at 65 °C for 12 hours.
Synthesis of Fe3O4@mSiO2 Nanostructures
For fabricating meso-silica covers over the prefabricated
magnetite nanoparticles, we used a modified Stöber
method [27] very similar to the method we reported earl-
ier [26]. About 10 mg of prefabricated magnetite nanopar-
ticles were dispersed in 50 mL of ethanol under ultrasonic
agitation. After that, the nanoparticles were magnetically
separated and redispersed in a 200-mL solution of water/
ethanol (1:4, v/v). Five milliliters of NH4OH (28 wt.%) was
added to the previous mixtures. After about 30 min of
stirring, 150 mg (0.41 mmol) of CTAB was added into thesolution, and the stirring was continued for further 30
min. Then, a desired amount of TEOS (0.05, 0.07, or 0.10
mL) was added to the mixture dropwise. After 24 hours of
mechanical stirring at room temperature, the nanostruc-
tures were magnetically separated, washed with ethanol
and water, and redispersed in 100 mL ethanol/acetic acid
(95:5, v/v) solution to remove CTAB from the sample.
After about 30 min of stirring, the precipitate was sepa-
rated magnetically, washed with water and ethanol several
times, and then dried in an oven at 80 °C for 24 hours.
The Fe3O4@mSiO2 composite nanoparticles synthesized
with 0.05 (0.22 mmol), 0.07 (0.31 mmol), and 0.10 mL
(0.45 mmol) of TEOS were named as samples SG-1, SG-2,
and SG-3, respectively.Characterization
Field emission high-resolution scanning electron micros-
copy (FE-HRSEM; Zeiss Auriga 3916, Carl Zeiss AG,
Oberkochen, Germany) and transmission electron micros-
copy (TEM, JEOL-JEM 211F operated at 200 keV, JEOL
Ltd., Tokyo, Japan) were used to determine the size and
morphology of the synthesized nanostructures. To deter-
mine the specific surface area of the samples, their N2
adsorption–desorption isotherms at 77 K were recorded
using Autosorb-1 Quantachrome Instrument sorptometer
(Quantachrome Instruments, Boynton Beach, FL, USA). A
UV–vis–NIR spectrophotometer (Cary 7000, Agilent
Technologies, Santa Clara, CA, USA) was used to monitor
the ibuprofen loading and releasing behavior of the
samples. A PPMS DynaCool (Quantum Design, San
Diego, CA, USA) system was used to measure the room
temperature magnetization curves (M vs. H) of the mag-
netite and meso-silica covered magnetite samples.Drug Loading in the Composite Nanoparticles
To test the drug-loading capacity of the Fe3O4@mSiO2
nanostructures, about 30 mg of each of the Fe3O4@m-
SiO2 samples (SG-1, SG-2, and SG-3) was separately
added into 10 mL of ibuprofen/hexane solution (30 mg/
Fig. 2 Room temperature magnetization curves for the naked and
meso-silica-covered magnetite clusters
Fig. 3 Typical TEM images of the a–c SG-1, d–f SG-2, and g–i SG-3 sample
shell thickness 15, 25, and 40 nm, respectively
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sealed vessel to prevent solution evaporation. After that,
the sample was separated magnetically, washed carefully
with hexane, and dried in vacuum at 60 °C for 24 hours.
The ibuprofen-loaded samples were named as ibu/SG-1,
ibu/SG-2, and ibu/SG-3.In Vitro Drug-Release From the Nanostructures
The prepared ibu/SGx (x = 1–3) samples were immersed
in 60 mL of simulated body fluid (SBF, pH = 7.4) under
slow stirring at 37 °C. The SBF was prepared following
the procedure reported by Chavan et al. [28]. In brief,
about 7.996 g of NaCl, 0.350 g of NaHCO3, 0.224 g of
KCl, 0.228 g of K2HPO4·3H2O, 0.305 g of MgCl2·6H2O,
0.278 g of CaCl2, 0.071 g of Na2SO4, and 6.057 g of
(CH2OH)3CNH2 were dissolved in 500 mL of deionized
(DI) water. Then, about 40 mL of 1 M HCl was added to
it. The total volume of the mixture was adjusted to 1 L by
adding DI water further to the previous mixture, obtaining
a solution of pH 7.4. The ratio of SBF to adsorbed ibu was
kept at 1 mL/mg in the mixture. At selected times, showing the formation of Fe3O4@mSiO2 core-shell structures with
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Fig. 4 N2 adsorption–desorption isotherms of a M-1 (Fe3O4), b SG-1, c SG-2, and d SG-3 samples and their pore size distribution (insets)
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ture solution, replacing by an equal volume (0.5 mL) of
fresh SBF. The amount of ibuprofen released was esti-
mated by monitoring the 263-nm absorption band of ibu-


























Fig. 5 UV absorption spectra of the ibuprofen–hexane solution before (bla
ibuprofen in the porous structures is clear from the reduction of absorption
around 263-nm absorption band of ibuprofenCell Culture
Human breast cancer cells (cell line MCF7) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, Waltham, MA, USA) supplemented with 10 %






ck line) and after loading SG-1, SG2, and SG-3 samples. Loading of
intensity (inset). The inset shows the magnified portion of the spectra
Table 1 Preparation conditions of the Fe3O4@mSiO2 samples, their texture properties and drug holding capacities
Composite sample Amount of used
TEOS (mL)
Average shell thickness (nm) aBET (m2/g) Pore radius rp (nm) Amount of loaded drug
(mgibu/gsample)
SG-1 0.05 15.0 363.2 1.08 678
SG-2 0.07 25.0 493.1 1.08 828
SG-3 0.10 40.0 543.0 1.08 954
Uribe Madrid et al. Nanoscale Research Letters  (2015) 10:217 Page 5 of 81× antibiotics (Invitrogen 15240-062, Gibco, containing
100 units penicillin and 100 μg of streptomycin per mL).
Human ovarian cancer cells (cell line SKOV3) were cul-
tured in Roswell Park Memorial Institute medium (RPMI
medium-1640) (HyClone, Logan, UT, USA) supplemented
with 10 % fetal bovine serum and 1× antibiotics. Normal
human lung fibroblast IMR-90 and MRC-5 cells were cul-
tured in Eagle’s Minimum Essential Medium (EMEM)
(Gibco, Waltham, MA, USA) supplemented with 10 %
fetal bovine serum and 1× antibiotics. The cultured
cells were maintained at 37 °C under 5 % CO2 in a
humid atmosphere.Cytotoxicity Assay
For this purpose, 2 × 104 MCF-4 cells, 1 × 104 SKOV3
cells, 2 × 104 MRC-5 cells, and 2 × 104 IMR-90 cells were
plated onto 35 mm dishes (SPL Life Science, Pocheon,
Korea) and cultured for 2 days. After 2 days, 2 mL of fresh
media were individually replaced with 20 μg/mL of M-1
(uncoated magnetite nanoparticles), SG-1, SG-2, or SG-3
samples. The cell viability tests were performed in tripli-
cates for each of the biological cells. The test cells were
monitored using an inverted phase-contrast microscope
after 2 days exposure to the magnetic samples. The num-


















Fig. 6 Release profiles of the ibuprofen loaded ibu/SG-1, ibu/SG-2,
and ibu/SG-3 samples in SBF solution at 37 °Ccell counter (Digital Bio, Seoul, Korea) attached with a
Nikon ECLIPSE TE300, Tokyo, Japan, microscope at ×100
magnification.
Results and Discussion
Figure 1 shows the typical SEM images of the magnetite
sample (M-1) synthesized by hydrothermal method. As
we can see, well-dispersed spherical nanoclusters of 100
to 300 nm diameters with an average size of 208 nm
were formed in the sample (Fig. 1 and Additional file 1:
Figure S3). It is very clear that the clusters are formed
through the agglomeration of smaller (~20 nm) particles
(primary particles). XRD analysis (Additional file 1:
Figure S1) of the sample revealed their spinel inverse
magnetite phase, with average grain size of about 20 nm
(using Scherrer relation).
The magnetization curve of the sample (M-1) presented
in Fig. 2 shows its superparamagnetic behavior with high
saturation magnetization (77.5 emu/g). This value is higher
than the Ms values reported by several research groups for
the MNPs prepared by different synthesis techniques
[29–31]. Such a high Ms value makes our superpara-
magnetic nanoparticles suitable for drug delivery appli-
cations. It should be noted that the Ms for bulk
magnetite is as high as 92 emu/g [32]. Although the Ms
value of the particles decreases about 25 % due to meso-
silica coating, apparently the thickness of the meso-
silica layer has no significant effect. On the other hand,
meso-silica layer over the magnetite nanoparticles re-
duces their coercivity (inset of Fig. 2). The high satur-
ation magnetization of the meso-silica coated magnetite
particles suggests their suitability for targeted drug de-
livery applications.
Using a modified Stöber method, mesoporous silica
layers were formed over the magnetite nanoclusters to
obtain Fe3O4@mSiO2 core-shell structures. Formation of
Fe3O4@mSiO2 nanostructures with silica shells of 15, 25,
and 40 nm average thicknesses can be seen in Fig. 3, for
the samples prepared using 0.05, 0.07, and 0.10 mL of
TEOS in the reaction mixtures, respectively. To make
the silica shell mesoporous, we used the cationic surfac-
tant CTAB as a polymer template during its growth,
which could be removed after the formation of silica layer
by rinsing in ethanol/acetic acid solution (95:5, v/v). The
complete removal of CTAB from the composite nano-
structures during this prolonged rinsing process has been
Uribe Madrid et al. Nanoscale Research Letters  (2015) 10:217 Page 6 of 8demonstrated in their FT-IR spectra (Additional file 1:
Figure S2).
The surface area and texture properties of the silica cov-
ered and naked magnetite particles were studied by re-
cording their N2 adsorption–desorption isotherms at 77 K
and are presented in Fig. 4. While the adsorption–desorp-
tion isotherm of the naked magnetite clusters (Fig. 4a) re-
vealed characteristics of both type II and type IV porous
materials (IUPAC classification) [33] due to inhomogen-
eous pore distribution, all the composite samples (SG-1,
SG-2, and SG-3) revealed the characteristics of type IV
mesoporous material, indicating their layered mesoporous






Fig. 7 Comparison of cytotoxic effects of magnetic beads on human breas
human lung fibroblasts MRC-5 and IMR-90. Panels a–d are the phase-contr
of MCF-7 (a), SKOV3 (b), MRC-5 (c), and IMR-90 (d) cell lines after magnetic
nanostructures in MCF-7, SKOV3, MRC-5, and IMR-90, respectivelyinterconnected primary particles of about 20 nm size (see
Additional file 1: Figure S3) formed by agglomeration
without any order, the mixed macro- and mesoporous na-
ture of the sample is understandable [34]. On the other
hand, the mesoporous nature of the composite particles
comes from the columnar outer silica layers formed by
replicating the lamellar structure of the polymer template
CTAB, formed over the magnetite clusters. From the pore
size distribution presented as inset of the Fig. 4b–d, we
can see that the pore size in all the silica-covered magnet-
ite samples is constant (≈2.16 nm). The BET estimated
specific surface area of the M-1, SG-1, SG-2, and SG-3
samples were of 42.3, 363.2, 493.1, and 543.0 m2/g,f)
h)
t cancer cell line MCF-7, ovarian cancer cell line SKOV3, and normal
ast microscopic images showing cell growth and colony morphology
beads treatments. Panels e–h show the cell viabilities of the used
Uribe Madrid et al. Nanoscale Research Letters  (2015) 10:217 Page 7 of 8respectively. Therefore, the specific surface area of the
composite nanostructures could be controlled by control-
ling the thickness of the meso-silica layer.
Figure 5 shows the UV–vis absorption spectra of ibu-
profen/hexane solution (30 mg/mL) before (black line)
and after loading the SG-1, SG-2, and SG-3 samples
(red, green, and blue line, respectively). As we can see, the
intensity of the typical 263-nm absorption band decreases
with the increase of shell thickness of the composite
particles, indicating a higher loading of ibuprofen for the
particles with higher meso-silica thickness. Using a pre-
calibrated absorbance curve of ibuprofen–hexane solution
(Additional file 1: Figure S4), the amount of drug loaded
in each of the composite samples could be determined.
The estimated amounts of ibuprofen loaded in the sam-
ples after 24 hours of impregnation under hexane solution
(under agitation at 25 °C) were 678, 828, and 954 mgibu/
mgsample, respectively (Table 1). Therefore, on increasing
the thickness of meso-silica layer over magnetite clusters,
a higher amount of drug could be loaded. The drug-
loading capacity of our composite nanoparticles is com-
parable to the drug-loading capacity of pure mesoporous
silica nanoparticles reported by Mei et al. [21].
Figure 6 shows the release profiles of the ibuprofen-
loaded SG-1, SG-2, and SG-3 samples up to 72 hours in
SBF solution. The amount of ibuprofen released in the
SBF solution was estimated from the absorption spectra
of the aliquots removed at different intervals. As can be
seen, after 72 hours in SBF solution, about 81, 79, and
74 % of ibuprofen were released from the samples ibu/
SG-1, ibu/SG-2, and ibu/SG-3, respectively. The release
rate is considerably faster for the first 6 hours, as the
drug incorporated at the porous surface of the nano-
structures is released initially. The drug incorporated
deeper inside the mesopores are released slowly, prob-
ably due to the strong capillary force acting on it. The
contribution of capillary force on the release of ibupro-
fen drug is clear if we consider its release rate from the
three samples during the initial 6 hours. The release rate
is highest for the sample ibu/SG-1 with smaller silica
shell thickness than the samples ibu/SG-2 and ibu/SG-3,
which contain silica shells of higher thicknesses. The re-
sults indicate that the ibuprofen release rate can be con-
trolled simply by controlling the thickness of the meso-
silica layer around magnetite clusters.
To investigate the cytotoxicity of these magnetic nano-
structures, the inhibitory potentials of M-1, SG-1, SG-2,
and SG-3 samples were analyzed by viable cell counting.
As shown in Fig. 7, these magnetic nanostructures have
limited effects on the cell morphology and viability on
human breast cancer line after incubation for 2 days at a
concentration of 20 μg/mL. After 48 hours of treatment,
samples M-1, SG-1, and SG-2 caused similar cytotoxicity
(~20 %) in MCF-7 cells. Cytotoxicity induced by SG-3sample was slightly higher (~25 %) than those of M-1,
SG-1, and SG-2 samples (Fig. 7a, e). To test for cell-line-
specific effects, we performed the same experiment in
human ovarian cancer line SKOV3 (Fig. 7b, f ) and in
two normal human lung fibroblasts MRC-5 (Fig. 7c, g)
and IMR-90 (Fig. 7d, h). The obtained results indicate
that the cytotoxicity of the meso-silica-covered magnet-
ite samples in normal human fibroblasts is a bit lower
than that in probed cancer cell lines. Thus, our cytotox-
icity tests through evaluation of cellular morphology and
cell growth kinetics revealed that on covering with
meso-silica layer, although the cytotoxicity of magnetite
nanoparticles increases a bit on cancer cell lines, it does
not change for normal human lung fibroblasts.
Conclusions
In summary, we demonstrate the synthesis of Fe3O4@m-
SiO2 core-shell type nanostructures of high surface area
(363, 493, and 543 m2/g) and ~2.16 nm of pore size,
with acceptable biocompatibility (~80 %) for drug deliv-
ery applications. The nanostructures can hold medicinal
drug such as ibuprofen as high as 954 mg/gsample, and
present a good release behavior up to 81 % of the loaded
drug. Covering magnetite nanoparticles by meso-silica
layers protects them from body fluids without affecting
their biocompatibility. Reasonable biocompatibility and
good drug release performance of the nanostructures
can be exploited for using them for targeted cancer and
non-cancer drug delivery applications in human body.
Additional file
Additional file 1: Figure S1. XRD patterns of the magnetite clusters
prepared through hydrothermal method. Figure S2 FT-IR spectra of (a)
Fe3O4@mSiO2 nanostructures (SG-3) before the acetic acid treatment and
(b) SG-1, (c) SG-2, (d) SG-3 after their acetic acid treatment. Figure S3
Typical high-resolution SEM image of the magnetite clusters prepared
by the hydrothermal method. Figure S4 a) UV absorption spectra of
ibuprofen/hexane solutions with different ibuprofen concentrations used
for preparing. b) Concentration calibration profile used for estimating
drug loading in Fe3O4@mSiO2 composite nanoclusters.
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